Today

Agents

Chat

Arena

Discover

More

App

Amylyx Pharmaceuticals Q2 posts higher than expected loss

A

AMLX

•

2026-08-06

Pipeline progress and cash runway

Company completed final study visit in pivotal Phase 3 LUCIDITY trial for avexitide
Topline data from Phase 3 LUCIDITY trial expected in late August or early September 2026
Company anticipates potential commercial launch of avexitide in 2027, if approved
Cash and investments were $250.8 mln and Amylyx expects cash runway to fund operations into 2028

Q2 loss missed analyst expectations

Biopharma firm's Q2 net loss and loss per share missed analyst expectations
Q2 loss per share was $0.39 versus consensus estimate of $0.36 from 9 analysts
Q2 net loss was $43.42 mln versus consensus estimate of $39.98 mln from 9 analysts
Q2 operating income was -$45.69 mln versus consensus estimate of -$42.32 mln from 9 analysts
Q2 operating expenses were $45.69 mln

Expense drivers and analyst coverage

Related News

Weak Fed and yen is Bessent's perfect pair trade

TLT•2026-08-06

Zscaler schedules fiscal Q4 2026 earnings call

ZS•2026-08-06

Karooooo CEO, Executive Chairman IJ Calisto disposes of USD 3.89 million in common shares

R&D spending decreased due to lower spending on AMX0035 for progressive supranuclear palsy, offset by higher costs for avexitide clinical development in PBH
SG&A costs increased due to higher legal expenses and increased investment in commercial strategic initiatives
Current average analyst rating on the shares is "buy", with 10 "strong buy" or "buy", 1 "hold", and no "sell" or "strong sell" ratings
Wall Street's median 12-month price target for Amylyx Pharmaceuticals, Inc. is $24.00, about 9.8% above its August 5 closing price of $21.85

2026-08-06

Rallybio swings to Q2 net income of $43.67 million; operating loss narrows to $5.65 million

RLYB•2026-08-06

Praxis Precision Q2 EPS USD -2.87

PRAX•2026-08-06

Amylyx Pharmaceuticals Q2 posts higher than expected loss - AMLX News | Rallies